Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PROCARBAZINE` `DRUG-LOMUSTINE` `DRUG-VINCRISTINE`

ID	`REG-RT-PCV-LGG`
Type	Regimen
Status	reviewed 2026-05-08 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-CNS-2025`

Notes

STUB — minimal entity to satisfy routing contract for IND-GLIOMA-LOW-GRADE-1L-RT-PCV. Based on RTOG 9802 PCV regimen (Buckner NEJM 2016, PMID 27050206). Requires clinical co-lead signoff before publication. The RT component (54 Gy/30 fx, conformal to tumor bed + 2 cm margin) is delivered first; PCV starts 4 weeks post-RT completion.

Used By

Algorithms

ALGO-GLIOMA-LGG-1L - ALGO-GLIOMA-LGG-1L

Drug

DRUG-LOMUSTINE - Lomustine (CCNU)

Indication

IND-GLIOMA-LOW-GRADE-1L-RT-PCV - IND-GLIOMA-LOW-GRADE-1L-RT-PCV